-
Pfizer Will Not Co-Promote Exact Sciences Colorectal Cancer Screening Test
Tuesday, November 30, 2021 - 7:15am | 269Read More...Exact Sciences Corporation (NASDAQ: EXAS) says that Pfizer Inc (NYSE: PFE) will no longer join the Company from November 30 to promote its Cologuard colorectal cancer screening test to health care providers. The decision follows an amendment to a co-promotion agreement signed by the...
-
FDA Signs Off Check-Cap's Pivotal Study For Capsule-Based Colorectal Cancer Screening Technology
Monday, March 15, 2021 - 7:34am | 222Read More...Check-Cap Ltd (NASDAQ: CHEK) stock is moving higher on heavy volume in the premarket session after the FDA approved its Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. C-Scan is the company's capsule-...
-
Humana To Begin Covering Exact Science's Cologuard In 2017
Friday, December 9, 2016 - 10:18am | 480Read More...Humana Inc (NYSE: HUM) has finally come around after showing intransigence in including EXACT Sciences Corporation (NASDAQ: EXAS)'s Cologuard test in its coverage policy. Humana's Commentary A Humana spokesperson told Benzinga exclusively that starting January 1, 2017, "Humana's Commercial members...
